相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation
Yishai Ofran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Eolia Brissot et al.
HAEMATOLOGICA (2019)
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
Justine Decroocq et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation
Avichai Shimoni et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia
Francesco Saraceni et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Eolia Brissot et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia
Y. S. Jethava et al.
BONE MARROW TRANSPLANTATION (2017)
Long-Term Outcome After a Treosulfan-Based Conditioning Regimen for Patients With Acute Myeloid Leukemia: a Report From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Arnon Nagler et al.
CANCER (2017)
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission
A. Ruggeri et al.
BONE MARROW TRANSPLANTATION (2016)
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Nicolaus Kroeger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis
Arnon Nagler et al.
LANCET HAEMATOLOGY (2015)
Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning
Anna Maria Raiola et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies
Paolo Di Bartolomeo et al.
BLOOD (2013)
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo
E. Todisco et al.
LEUKEMIA (2013)
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
I. Danylesko et al.
BONE MARROW TRANSPLANTATION (2012)
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
A. Shimoni et al.
BONE MARROW TRANSPLANTATION (2012)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia
Jaime Sanz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Juergen Finke et al.
LANCET ONCOLOGY (2009)
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
Mohamed Sorror et al.
CANCER (2008)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
N Kröger et al.
BONE MARROW TRANSPLANTATION (2006)
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
AA Oyekunle et al.
BONE MARROW TRANSPLANTATION (2006)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
C Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treosulfan and fludarabine:: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
J Casper et al.
BLOOD (2004)
Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia
S Singhal et al.
BONE MARROW TRANSPLANTATION (2002)
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
A Bacigalupo et al.
BLOOD (2001)
分享论文
